MX2022012898A - Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta. - Google Patents
Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.Info
- Publication number
- MX2022012898A MX2022012898A MX2022012898A MX2022012898A MX2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A
- Authority
- MX
- Mexico
- Prior art keywords
- solvate
- hydrate
- pharmaceutically acceptable
- acceptable salt
- oral administration
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title abstract 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción proporciona una composición farmacéutica para administración oral que comprende N-(5-(4-(4-((dimetilamino)m etil)-3-fenil-1H-pirazol-1-il)pirimidina-2-ilamino)-4-metoxi-2-mo rfolinofenil)acrilamida o una sal, hidrato o solvato farmacéuticamente aceptable de esta como un ingrediente activo; y una combinación de (i) un derivado de celulosa y (ii) un azúcar o poliol como diluyentes. Las composiciones descritas se caracterizan por una capacidad de fabricación mejorada, mientras se mantienen los beneficios farmacéuticos de minimizar el efecto de acuerdo con cambios en el entorno de pH en el estómago, poseen excelente estabilidad, y exhiben buena biodisponibilidad.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009623P | 2020-04-14 | 2020-04-14 | |
| US202063014277P | 2020-04-23 | 2020-04-23 | |
| PCT/IB2021/053035 WO2021209893A1 (en) | 2020-04-14 | 2021-04-13 | Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012898A true MX2022012898A (es) | 2023-01-24 |
Family
ID=75562794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012898A MX2022012898A (es) | 2020-04-14 | 2021-04-13 | Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210322323A1 (es) |
| EP (1) | EP4135669A1 (es) |
| JP (1) | JP2023522634A (es) |
| KR (1) | KR20230002656A (es) |
| CN (1) | CN115484937A (es) |
| AU (1) | AU2021257662A1 (es) |
| BR (1) | BR112022020609A2 (es) |
| CA (1) | CA3180184A1 (es) |
| IL (1) | IL297240A (es) |
| MX (1) | MX2022012898A (es) |
| TW (1) | TW202207940A (es) |
| UY (1) | UY39171A (es) |
| WO (1) | WO2021209893A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| EP4349835A1 (en) * | 2021-06-01 | 2024-04-10 | Hangzhou Solipharma Co., Ltd. | Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof |
| WO2023138492A1 (zh) * | 2022-01-19 | 2023-07-27 | 南京明德新药研发有限公司 | 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6437006B1 (en) * | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
| JP2010507676A (ja) * | 2006-10-27 | 2010-03-11 | エフ エム シー コーポレーション | 乾式顆粒化結合剤、生成物およびその使用 |
| EP2198857A1 (en) * | 2008-12-19 | 2010-06-23 | Ratiopharm GmbH | Oral dispersible tablet |
| ES2700231T3 (es) | 2012-11-21 | 2019-02-14 | Janssen Biotech Inc | Anticuerpos de EGFR/c-Met biespecíficos |
| US20160151380A1 (en) * | 2013-07-12 | 2016-06-02 | The Regents Of The University Of California | Therapies for diseases caused by arthropod-borne parasites |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| CN106795144B (zh) | 2014-10-13 | 2020-06-16 | 株式会社柳韩洋行 | 用于调节egfr突变体激酶活性的化合物和组合物 |
| EP3439653B1 (en) * | 2016-04-07 | 2021-01-20 | ChemoCentryx, Inc. | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| CA3049452A1 (en) * | 2017-01-20 | 2018-07-26 | Gisela Schwab | Combinations of cabozantinib and atezolizumab to treat cancer |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
-
2021
- 2021-04-12 TW TW110113031A patent/TW202207940A/zh unknown
- 2021-04-13 CN CN202180028642.0A patent/CN115484937A/zh active Pending
- 2021-04-13 KR KR1020227039484A patent/KR20230002656A/ko active Search and Examination
- 2021-04-13 WO PCT/IB2021/053035 patent/WO2021209893A1/en active Application Filing
- 2021-04-13 AU AU2021257662A patent/AU2021257662A1/en active Pending
- 2021-04-13 US US17/228,753 patent/US20210322323A1/en active Pending
- 2021-04-13 UY UY0001039171A patent/UY39171A/es unknown
- 2021-04-13 JP JP2022562451A patent/JP2023522634A/ja active Pending
- 2021-04-13 CA CA3180184A patent/CA3180184A1/en active Pending
- 2021-04-13 EP EP21719733.4A patent/EP4135669A1/en active Pending
- 2021-04-13 IL IL297240A patent/IL297240A/en unknown
- 2021-04-13 BR BR112022020609A patent/BR112022020609A2/pt unknown
- 2021-04-13 MX MX2022012898A patent/MX2022012898A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210322323A1 (en) | 2021-10-21 |
| EP4135669A1 (en) | 2023-02-22 |
| IL297240A (en) | 2022-12-01 |
| JP2023522634A (ja) | 2023-05-31 |
| UY39171A (es) | 2021-10-29 |
| KR20230002656A (ko) | 2023-01-05 |
| WO2021209893A8 (en) | 2022-10-13 |
| BR112022020609A2 (pt) | 2022-11-29 |
| CA3180184A1 (en) | 2021-10-21 |
| AU2021257662A1 (en) | 2022-12-15 |
| WO2021209893A1 (en) | 2021-10-21 |
| TW202207940A (zh) | 2022-03-01 |
| CN115484937A (zh) | 2022-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012898A (es) | Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta. | |
| MX2023012361A (es) | Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo. | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| SE0400284D0 (sv) | Novel compounds | |
| WO2021012049A8 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
| NO20080670L (no) | Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| IN266803B (es) | ||
| MX2022013054A (es) | Derivados de imidazolidinona y uso medico de los mismos. | |
| EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| CR20220638A (es) | Derivados de amidopirimidona | |
| MX2023014946A (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal. | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| ATE473212T1 (de) | Hiv-inhibierende 2-(4-cyanophenyl)-6- hydroxylaminopyrimidine | |
| MX2009007040A (es) | Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular. | |
| SA523442503B1 (ar) | مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| EA200970570A1 (ru) | Макролидные соединения, обладающие противовоспалительной активностью | |
| MX2023008562A (es) | Derivados de pirazolamida. | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| NZ543068A (en) | Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| CR20220644A (es) | Derivados de sulfona |